DMK Pharmaceuticals Corporation (DMKPQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DMK Pharmaceuticals Corporation (DMKPQ) with AI Score 61/100 (Hold). DMK Pharmaceuticals Corporation is a clinical-stage neuro-biotechnology company focused on developing and commercializing products for allergy, opioid overdose, respiratory, and inflammatory diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026DMK Pharmaceuticals Corporation (DMKPQ) Healthcare & Pipeline Overview
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals, is a clinical-stage neuro-biotechnology company developing therapies for allergy, opioid overdose, and respiratory conditions. Currently undergoing Chapter 11 reorganization, DMKPQ navigates a competitive landscape with products like SYMJEPI and ZIMHI, while focusing on its lead candidate DPI-125 for opioid use disorder.
Investment Thesis
DMK Pharmaceuticals Corporation presents a high-risk, high-reward investment profile, particularly given its Chapter 11 reorganization filing in February 2024. The company's value hinges on the successful restructuring and advancement of its lead clinical candidate, DPI-125, targeting opioid use disorder. Key value drivers include potential FDA approval for DPI-125 and successful commercialization of existing products like SYMJEPI and ZIMHI post-reorganization. However, the company's negative profit margin of -556.7% and gross margin of -60.9% underscore significant financial challenges. Upcoming milestones include navigating the bankruptcy process and securing funding for continued operations and clinical trials. Investors should closely monitor the company's progress in restructuring its debt and achieving operational efficiency.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B reflects the company's current financial distress and Chapter 11 status.
- Negative Profit Margin of -556.7% indicates substantial losses and operational inefficiencies.
- Gross Margin of -60.9% highlights challenges in pricing and cost management for its products.
- Beta of 0.79 suggests lower volatility compared to the overall market.
- No dividend is currently offered, reflecting the company's focus on reinvesting capital into its operations and restructuring efforts.
Competitors & Peers
Strengths
- Specialized product portfolio in allergy and opioid overdose.
- Established brand recognition for SYMJEPI and ZIMHI.
- Clinical-stage product candidate DPI-125 with potential for significant revenue.
- Experienced management team with expertise in drug development.
Weaknesses
- Chapter 11 bankruptcy filing indicates severe financial distress.
- Negative profit and gross margins reflect operational inefficiencies.
- Limited financial resources for research and development.
- Dependence on regulatory approvals for product commercialization.
Catalysts
- Upcoming: Successful navigation of Chapter 11 bankruptcy proceedings by the end of 2026.
- Upcoming: Potential FDA approval and commercialization of DPI-125 for opioid use disorder, timeline dependent on funding.
- Ongoing: Strategic partnerships with larger pharmaceutical companies to co-develop and commercialize products.
- Ongoing: Expansion of SYMJEPI market share through increased distribution and awareness.
- Ongoing: Continued research and development efforts to expand product pipeline.
Risks
- Ongoing: Chapter 11 bankruptcy poses a significant threat to the company's survival.
- Potential: Regulatory hurdles and delays in product approvals could impede commercialization.
- Potential: Intense competition from established pharmaceutical companies may limit market share.
- Potential: Product liability claims and litigation risks associated with pharmaceutical products.
- Potential: Changes in healthcare policies and reimbursement rates could impact revenue.
Growth Opportunities
- Advancement of DPI-125: DMK's lead clinical candidate, DPI-125, targets opioid use disorder, a market projected to reach billions of dollars. Successful completion of clinical trials and FDA approval could significantly boost DMK's revenue and market share. The timeline for potential approval is dependent on the Chapter 11 reorganization and subsequent funding for clinical trials.
- Expansion of SYMJEPI Market: SYMJEPI, an epinephrine injection for allergic reactions, has the potential for increased market penetration. The global epinephrine market is expected to grow, driven by rising allergy rates. DMK can capitalize on this trend by expanding its distribution network and increasing awareness of SYMJEPI's benefits. This expansion is contingent on the company's financial restructuring.
- Strategic Partnerships: DMK can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its products. These partnerships can provide access to additional funding, expertise, and distribution channels. The timeline for securing such partnerships depends on DMK's ability to demonstrate the value of its pipeline and products.
- Geographic Expansion: DMK can expand its geographic reach by entering new markets outside the United States. This expansion can increase its customer base and revenue streams. The timeline for international expansion is dependent on regulatory approvals and market entry strategies.
- Acquisition of Complementary Assets: DMK can acquire complementary assets or technologies to expand its product portfolio and capabilities. These acquisitions can enhance its competitive position and drive long-term growth. The feasibility of acquisitions is contingent on the company's financial restructuring and access to capital.
Opportunities
- Growing market for opioid overdose treatments and allergy therapies.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Expansion into new geographic markets.
- Acquisition of complementary assets or technologies.
Threats
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles and delays in product approvals.
- Product liability claims and litigation risks.
- Changes in healthcare policies and reimbursement rates.
Competitive Advantages
- Proprietary formulations and drug delivery systems.
- Patent protection for its key products and technologies.
- Established brand recognition for SYMJEPI and ZIMHI.
- Specialized expertise in allergy and opioid overdose therapies.
About DMKPQ
DMK Pharmaceuticals Corporation, previously known as Adamis Pharmaceuticals Corporation until its name change in September 2023, is a clinical-stage neuro-biotechnology company dedicated to developing and commercializing products targeting allergy, opioid overdose, respiratory, and inflammatory diseases. Founded with the mission of addressing unmet medical needs, the company is headquartered in San Diego, California. DMK's portfolio includes SYMJEPI, an epinephrine injection for emergency treatment of allergic reactions, and ZIMHI, a naloxone injection designed to combat opioid overdose. The company's pipeline is anchored by DPI-125, a clinical-stage product candidate aimed at treating opioid use disorder. DMK Pharmaceuticals has navigated a challenging path, culminating in a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on February 2, 2024. This strategic move aims to restructure the company's finances and operations to ensure long-term sustainability. Despite the financial headwinds, DMK remains committed to advancing its therapeutic programs and delivering innovative solutions to patients in need. The company's focus on specialized areas like allergy and opioid overdose positions it within a critical segment of the healthcare industry, addressing significant public health concerns.
What They Do
- Develops and commercializes products for allergy, opioid overdose, respiratory, and inflammatory diseases.
- Offers SYMJEPI epinephrine injection for emergency treatment of allergic reactions.
- Provides ZIMHI naloxone injection for the treatment of opioid overdose.
- Focuses on DPI-125, a clinical-stage product candidate for opioid use disorder.
- Engages in research and development of neuro-biotechnology therapies.
- Aims to address unmet medical needs in specialized therapeutic areas.
Business Model
- Develops pharmaceutical products through research and clinical trials.
- Seeks regulatory approval from agencies like the FDA.
- Manufactures and markets its approved products.
- Generates revenue through product sales.
Industry Context
DMK Pharmaceuticals Corporation operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and regulatory scrutiny. The market for opioid overdose treatments and allergy therapies is substantial, driven by increasing prevalence and public health initiatives. DMK's competitors include companies like ADLI, AMHD, BIMI, CFRXQ, and EFTR. The industry is witnessing a growing emphasis on innovative drug delivery systems and personalized medicine, with companies striving to differentiate themselves through novel formulations and targeted therapies. DMK's success depends on its ability to navigate regulatory hurdles, secure funding, and effectively commercialize its products in a dynamic market.
Key Customers
- Patients requiring emergency treatment for allergic reactions.
- Individuals suffering from opioid overdose.
- Healthcare providers prescribing allergy and opioid overdose treatments.
- Hospitals and clinics administering emergency medications.
Financials
Chart & Info
DMK Pharmaceuticals Corporation (DMKPQ) stock price: Price data unavailable
Latest News
No recent news available for DMKPQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMKPQ.
Price Targets
Wall Street price target analysis for DMKPQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates DMKPQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Eddie Wabern Glover
CEO
Eddie Wabern Glover serves as the CEO of DMK Pharmaceuticals Corporation, leading a team of 11 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining DMK Pharmaceuticals, Glover held leadership positions at various healthcare companies, focusing on strategic planning, product development, and commercialization. He has a proven track record of driving growth and innovation in the pharmaceutical sector.
Track Record: Under Eddie Wabern Glover's leadership, DMK Pharmaceuticals has focused on advancing its clinical pipeline, particularly DPI-125 for opioid use disorder. He has overseen the company's efforts to navigate the complex regulatory landscape and secure funding for its research and development programs. However, his tenure has also been marked by the company's Chapter 11 bankruptcy filing, presenting significant challenges for the future.
DMKPQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DMK Pharmaceuticals Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide comprehensive financial disclosures, increasing the risk for investors. Trading on the OTC Other tier differs significantly from exchanges like NYSE or NASDAQ, which have stricter listing requirements and greater regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in DMKPQ.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- The OTC Other tier lacks the regulatory oversight of major exchanges.
- Chapter 11 bankruptcy adds significant uncertainty to the company's future.
- Potential for delisting and loss of investment.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business plan and growth prospects.
- Understand the risks associated with investing in OTC Other stocks.
- Monitor the company's progress in Chapter 11 reorganization.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- The company has existing products on the market (SYMJEPI and ZIMHI).
- DMK Pharmaceuticals has a clinical-stage product candidate (DPI-125).
- The company is focused on addressing unmet medical needs in allergy and opioid overdose.
- DMK Pharmaceuticals has been in operation since before its name change in 2023.
- The company has a CEO.
DMK Pharmaceuticals Corporation Stock: Key Questions Answered
What does DMK Pharmaceuticals Corporation do?
DMK Pharmaceuticals Corporation is a clinical-stage neuro-biotechnology company focused on developing and commercializing pharmaceutical products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. Its key products include SYMJEPI, an epinephrine injection for allergic reactions, and ZIMHI, a naloxone injection for opioid overdose. The company's lead clinical candidate, DPI-125, targets opioid use disorder. Currently undergoing Chapter 11 reorganization, DMK aims to restructure its finances and operations to ensure long-term sustainability and advance its therapeutic programs.
What do analysts say about DMKPQ stock?
AI analysis is currently pending for DMKPQ. Given the company's Chapter 11 bankruptcy filing and OTC Other listing, traditional analyst coverage may be limited. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in distressed companies. Key valuation metrics are currently negative due to the company's financial challenges. Growth considerations hinge on the successful restructuring and advancement of its clinical pipeline, particularly DPI-125.
What are the main risks for DMKPQ?
The primary risk for DMK Pharmaceuticals Corporation is its Chapter 11 bankruptcy filing, which introduces significant uncertainty regarding the company's future viability. Additional risks include regulatory hurdles and delays in product approvals, intense competition from established pharmaceutical companies, product liability claims, and changes in healthcare policies and reimbursement rates. Investing in OTC Other stocks like DMKPQ carries inherent risks due to limited financial disclosure and low trading volume.
What are the key factors to evaluate for DMKPQ?
DMK Pharmaceuticals Corporation (DMKPQ) currently holds an AI score of 61/100, indicating moderate score. Key strength: Specialized product portfolio in allergy and opioid overdose.. Primary risk to monitor: Ongoing: Chapter 11 bankruptcy poses a significant threat to the company's survival.. This is not financial advice.
How frequently does DMKPQ data refresh on this page?
DMKPQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DMKPQ's recent stock price performance?
Recent price movement in DMK Pharmaceuticals Corporation (DMKPQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product portfolio in allergy and opioid overdose.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DMKPQ overvalued or undervalued right now?
Determining whether DMK Pharmaceuticals Corporation (DMKPQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DMKPQ?
Before investing in DMK Pharmaceuticals Corporation (DMKPQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- The company's Chapter 11 bankruptcy status introduces significant uncertainty.
- AI analysis is pending and may provide additional insights.